Sabcomeline Hydrochloride

Sabcomeline had been in phase III clinical trials for the treatment of Alzheimer's disease (AD) and phase II for schizophrenia and major depressive disorder (MDD).  

This compound was originally discovered by GlaxoSmithKline, licensed to Minster Pharmaceuticals (acquired by Proximagen in 2010) in 2001, then acquired by BrainCells in 2010. However, the researches about this drug candidate were discontinued.

Index：

General Information

Update Date：2016-05-26

Drug Name：
Sabcomeline Hydrochloride
Research Code：
BCI-224; BRL-55473; CEB-2424; SB-202026A
Trade Name：
MOA：
Muscarinic M1 receptor agonist
Indication：
Alzheimer's disease (AD)
Status：
Phase Ⅲ (Discontinued)
Company：
GlaxoSmithKline (Originator) , Proximagen,BrainCells
Sales：
ATC Code：
Chemical Structure

Update Date：2016-02-03

Molecular Weight 229.71
Formula C10H15N3O • HCl
CAS No. 159912-53-5 (Sabcomeline);
159912-58-0 (Sabcomeline hydrochloride);
Chemical Name 1-Azabicyclo[2.2.2]octane-3-acetonitrile, a-(methoxyimino)-, hydrochloride (1:1), (aZ,3R)-
Sabcomeline （Free Acid/Base）Parameters：
MW HD HA FRB* PSA* cLogP*
193.25 0 4 2 48.6 1.389±0.519
*：Calculated by ACD/Labs software V11.02.
Synthesis & Impurities

Update Date：2016-04-08


1. J. Chem. Soc., Chem. Commun. 1994, 18, 2189-2190.

2. J. Med. Chem. 1997, 40, 4265-4280.


1. US5675007.

Impurity database is being updated！